(Q38641139)

5 September 2017

title

Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy (English)

1 reference

5 September 2017

main subject

personalized medicine

1 reference

1 reference

1

1 reference

5 September 2017

Jacques Robert

2

0 references

language of work or name

1 reference

20 November 2015

1 reference

Cancer Chemotherapy and Pharmacology

5 September 2017

published in

1 reference

5 September 2017

volume

77

1 reference

5 September 2017

issue

1

1 reference

5 September 2017

page(s)

5-18

1 reference

Oxaliplatin for colorectal cancer in the United States: better late than never

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Oxaliplatin: a review of preclinical and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Strategies to improve the efficacy of platinum compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Polymorphic transporters and platinum pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Organic cation transporters are determinants of oxaliplatin cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

ABC transporters as potential targets for modulation of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

What do drug transporters really do?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

ABC transporters in cancer: more than just drug efflux pumps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Cellular processing of platinum anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Recognition and processing of cisplatin- and oxaliplatin-DNA adducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

A role for polymerase eta in the cellular tolerance to cisplatin-induced damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

DNA polymerase ζ is a major determinant of resistance to platinum-based chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

A review of excision repair cross-complementation group 1 in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Cancer treatment according to BRCA1 and BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Flt-1-Dependent Survival Characterizes the Epithelial-Mesenchymal Transition of Colonic Organoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Molecular mechanisms of ATP secretion during immunogenic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Trial watch: Immunostimulatory cytokines in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2901-X

10.1007/S00280-015-2901-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

1039413417

0 references

1 reference